🇺🇸 FDA
Pipeline program

Sintilimab injection plus Inlyta treatment

20190813

Phase 2 small_molecule active

Quick answer

Sintilimab injection plus Inlyta treatment for Carcinoma, Renal Cell is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Carcinoma, Renal Cell
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials